Show Search Form
registered interest | ![]() |
![]() |
|||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
date | ![]() ![]() ![]() |
||||||||||||||||||||||||||||||
answering body |
|
||||||||||||||||||||||||||||||
answering dept id | 17 | ![]() |
|||||||||||||||||||||||||||||
answering dept short name | Health and Social Care | ![]() |
|||||||||||||||||||||||||||||
answering dept sort name | Health and Social Care | ![]() |
|||||||||||||||||||||||||||||
hansard heading | Tixagevimab/cilgavimab | ![]() |
|||||||||||||||||||||||||||||
house id | 2 | ![]() |
|||||||||||||||||||||||||||||
legislature |
|
||||||||||||||||||||||||||||||
question text | To ask His Majesty's Government, further to the Written Answer by Lord Markham on 6 March (HL5937), why the National Institute for Clinical Excellence (NICE) request for referral of 8 June is described as for “referral of Evusheld for treatment of COVID-19” but, as confirmed in a NICE freedom of information response, the request was for “referral of tixagevimab-cilgavimab for preventing COVID-19 [ID6136] on 8 June 2022”, causing delay to the possibility of a decision at a time when the preventative prophylaxis Evusheld was highly efficacious. | ![]() |
|||||||||||||||||||||||||||||
tabling member printed |
|
||||||||||||||||||||||||||||||
uin | HL6531 | ![]() |
|||||||||||||||||||||||||||||
answer |
|
||||||||||||||||||||||||||||||
tabling member |
|